

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.7	68.7	(25.1-149.5)	Male	9	5.8	156.4	(71.4-296.9)
Female	2	2.5	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	37	29.8	124.2	(87.4-171.2)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	8	10.7	74.8	(32.2-147.4)	<u>Ovary</u>				
Female	8	8.1	98.8	(42.5-194.7)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	36	35.2	102.3	(71.6-141.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	3	4.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	6	5.1	117.6	(42.9-256.0)
Male	0	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.6	nc	(nc-nc)	Male	94	120.0	78.4	(63.3-95.9)
Female	2	0.7	nc	(nc-nc)	Female	99	96.8	102.2	(83.1-124.5)
<u>Lung and Bronchus</u>									
Male	7	16.0	43.7	(17.5-90.0)					
Female	12	13.4	89.3	(46.1-156.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	21.8	110.3	(70.6-164.1)	Male	18	14.3	125.6	(74.4-198.4)
Female	4	8.5	nc	(nc-nc)	Female	16	11.7	137.2	(78.4-222.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	12.4	96.7	(49.9-168.8)
Female	81	86.9	93.2	(74.0-115.8)	Female	5	10.8	46.3	(14.9-107.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	10	9.0	111.1	(53.2-204.4)
<u>Colon / Rectum</u>					Female	2	4.3	nc	(nc-nc)
Male	29	26.7	108.7	(72.8-156.1)	<u>Ovary</u>				
Female	30	28.3	105.9	(71.4-151.1)	Female	10	8.3	120.0	(57.5-220.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.9	nc	(nc-nc)	Male	6	7.1	84.5	(30.9-184.0)
Female	3	1.7	nc	(nc-nc)	Female	7	8.1	86.4	(34.6-178.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	66	86.1	76.7	(59.3-97.5)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.1	nc	(nc-nc)
Male	12	12.0	100.4	(51.8-175.4)	Female	5	3.3	152.8	(49.3-356.7)
Female	3	7.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	16	14.5	110.4	(63.0-179.2)
Male	8	7.8	102.5	(44.1-201.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.2	81.0	(26.1-189.1)	Female	12	20.1	59.8	(30.9-104.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.6	nc	(nc-nc)	Male	259	297.5	87.1	(76.8-98.3)
Female	4	2.3	nc	(nc-nc)	Female	277	301.0	92.0	(81.5-103.5)
<u>Lung and Bronchus</u>									
Male	36	40.6	88.7	(62.1-122.8)					
Female	45	42.5	106.0	(77.3-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	90	93.8	95.9	(77.1-117.9)	Male	75	59.1	127.0	(99.9-159.2)
Female	35	33.3	105.0	(73.1-146.1)	Female	60	47.2	127.1	(97.0-163.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	22	16.9	129.8	(81.3-196.5)	Male	18	15.2	118.0	(69.9-186.6)
Female	18	14.9	120.6	(71.4-190.6)	Female	13	12.0	108.6	(57.8-185.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.7	nc	(nc-nc)	Male	62	52.2	118.8	(91.1-152.3)
Female	474	332.4	142.6	(130.1-156.0)	Female	51	42.9	118.9	(88.5-156.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	12.7	71.1	(32.5-135.1)	Male	38	35.2	107.9	(76.4-148.1)
<u>Colon / Rectum</u>					Female	23	16.8	137.0	(86.8-205.5)
Male	96	111.4	86.1	(69.8-105.2)	<u>Ovary</u>				
Female	118	111.2	106.1	(87.8-127.1)	Female	40	32.6	122.6	(87.6-167.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	23.7	29.6	(11.8-60.9)	Male	32	29.9	107.1	(73.2-151.2)
Female	5	6.8	73.7	(23.7-171.9)	Female	32	31.7	100.8	(69.0-142.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	7.5	nc	(nc-nc)	Male	393	338.9	116.0	(104.8-128.0)
Female	5	7.0	71.4	(23.0-166.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	22	21.5	102.5	(64.2-155.2)
Male	48	47.7	100.7	(74.3-133.6)	Female	10	12.9	77.7	(37.2-142.9)
Female	30	27.9	107.7	(72.6-153.7)	<u>Testis</u>				
<u>Larynx</u>					Male	17	11.6	146.6	(85.3-234.7)
Male	11	13.7	80.1	(40.0-143.4)	<u>Thyroid</u>				
Female	1	3.9	nc	(nc-nc)	Male	27	18.2	148.2	(97.6-215.6)
<u>Leukemia</u>					Female	93	59.4	156.6	(126.4-191.9)
Male	30	34.1	88.1	(59.4-125.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	23	25.0	91.9	(58.2-137.9)	Female	78	75.7	103.0	(81.4-128.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	25.7	97.1	(62.8-143.4)	Male	1221	1223.3	99.8	(94.3-105.6)
Female	8	9.0	89.1	(38.4-175.6)	Female	1384	1177.2	117.6	(111.5-123.9)
<u>Lung and Bronchus</u>									
Male	99	168.6	58.7	(47.7-71.5)					
Female	151	166.3	90.8	(76.9-106.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.6	62.8	(22.9-136.7)	Male	6	8.2	72.9	(26.6-158.7)
Female	4	2.2	nc	(nc-nc)	Female	7	3.9	179.3	(71.8-369.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	10	7.0	142.8	(68.4-262.6)
Female	42	28.6	147.1	(106.0-198.8)	Female	5	3.1	162.6	(52.4-379.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	10	13.7	73.1	(35.0-134.5)	<u>Ovary</u>				
Female	7	7.6	92.0	(36.9-189.5)	Female	0	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.1	nc	(nc-nc)	Male	5	3.4	147.9	(47.7-345.2)
Female	3	0.4	nc	(nc-nc)	Female	5	2.0	244.2	(78.7-570.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	51	46.7	109.3	(81.4-143.7)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.5	nc	(nc-nc)
Male	8	7.2	111.7	(48.1-220.1)	Female	1	0.8	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	12	5.7	210.6	(108.7-367.9)
Male	4	4.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	13	6.3	206.0	(109.6-352.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	3.9	204.9	(88.2-403.8)	Male	148	158.9	93.1	(78.7-109.4)
Female	0	0.7	nc	(nc-nc)	Female	124	91.4	135.6	(112.8-161.7)
<u>Lung and Bronchus</u>									
Male	10	19.2	52.1	(24.9-95.8)					
Female	10	11.4	88.0	(42.1-161.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	15.2	131.4	(80.2-202.9)	Male	10	9.5	105.3	(50.4-193.6)
Female	5	6.7	74.4	(24.0-173.7)	Female	4	8.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	8.5	94.5	(40.7-186.3)
Female	49	59.3	82.6	(61.1-109.2)	Female	6	8.3	72.5	(26.5-157.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	9	5.5	163.5	(74.6-310.4)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	21	17.9	117.3	(72.6-179.3)	<u>Ovary</u>				
Female	34	22.4	151.7	(105.1-212.1)	Female	4	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	3.7	271.1	(129.8-498.6)	Male	7	4.8	146.7	(58.8-302.3)
Female	3	1.4	nc	(nc-nc)	Female	10	6.5	154.4	(73.9-284.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	61	50.8	120.1	(91.8-154.2)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	6	7.6	78.8	(28.8-171.5)	Female	8	2.6	303.1	(130.5-597.2)
Female	4	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.2	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	8	9.6	83.6	(36.0-164.8)
Male	5	5.5	90.5	(29.2-211.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.8	124.1	(45.3-270.0)	Female	16	12.9	124.0	(70.8-201.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.1	123.2	(39.7-287.5)	Male	246	193.4	127.2	(111.8-144.1)
Female	0	1.7	nc	(nc-nc)	Female	227	219.6	103.4	(90.4-117.7)
<u>Lung and Bronchus</u>									
Male	53	27.1	195.9	(146.7-256.2)					
Female	48	32.9	145.9	(107.6-193.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	27.4	105.7	(70.8-151.8)	Male	25	18.6	134.2	(86.8-198.1)
Female	19	9.9	191.2	(115.1-298.6)	Female	19	14.6	130.2	(78.3-203.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.6	124.4	(49.8-256.2)	Male	5	4.6	107.7	(34.7-251.3)
Female	3	4.6	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	13	16.2	80.1	(42.6-136.9)
Female	122	102.9	118.6	(98.5-141.6)	Female	15	12.9	116.0	(64.9-191.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.1	nc	(nc-nc)	Male	13	11.5	113.3	(60.3-193.8)
<u>Colon / Rectum</u>					Female	10	5.1	197.7	(94.6-363.6)
Male	33	34.0	97.1	(66.8-136.4)	<u>Ovary</u>				
Female	40	33.8	118.3	(84.5-161.1)	Female	14	9.8	142.8	(78.0-239.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	7.3	123.3	(56.3-234.1)	Male	9	9.0	100.5	(45.8-190.7)
Female	1	2.0	nc	(nc-nc)	Female	16	9.5	168.0	(96.0-272.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	119	104.9	113.5	(94.0-135.8)
Female	4	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.4	nc	(nc-nc)
Male	15	15.4	97.5	(54.5-160.8)	Female	5	3.9	128.5	(41.4-299.8)
Female	8	8.5	94.7	(40.8-186.6)	<u>Testis</u>				
<u>Larynx</u>					Male	8	4.0	198.1	(85.3-390.4)
Male	3	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	9	6.3	142.0	(64.8-269.6)
<u>Leukemia</u>					Female	20	18.9	105.8	(64.6-163.5)
Male	10	10.4	96.2	(46.0-176.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	7.8	167.6	(89.1-286.6)	Female	16	22.5	71.1	(40.6-115.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.3	60.6	(19.5-141.3)	Male	396	376.7	105.1	(95.0-116.0)
Female	2	2.7	nc	(nc-nc)	Female	431	358.6	120.2	(109.1-132.1)
<u>Lung and Bronchus</u>									
Male	39	50.8	76.8	(54.6-105.0)					
Female	57	49.3	115.5	(87.5-149.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	25.5	47.0	(24.3-82.1)	Male	31	18.2	170.5	(115.9-242.1)
Female	11	9.0	122.7	(61.2-219.6)	Female	16	14.4	111.3	(63.6-180.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.5	144.4	(62.2-284.6)	Male	1	4.4	nc	(nc-nc)
Female	6	4.5	133.9	(48.9-291.5)	Female	4	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	11	15.7	70.1	(35.0-125.5)
Female	107	103.4	103.5	(84.8-125.0)	Female	10	12.0	83.1	(39.8-152.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.3	nc	(nc-nc)	Male	6	11.5	52.0	(19.0-113.1)
<u>Colon / Rectum</u>					Female	5	5.0	100.8	(32.5-235.2)
Male	30	32.0	93.7	(63.2-133.8)	<u>Ovary</u>				
Female	35	30.4	115.0	(80.1-159.9)	Female	9	9.7	93.2	(42.5-176.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.3	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	12	8.4	142.0	(73.3-248.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.6	nc	(nc-nc)	Male	105	109.1	96.2	(78.7-116.5)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.1	nc	(nc-nc)
Male	11	15.3	71.9	(35.9-128.7)	Female	0	3.5	nc	(nc-nc)
Female	8	8.1	98.7	(42.5-194.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.3	117.3	(37.8-273.8)
Male	8	4.3	186.2	(80.2-367.0)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
<u>Leukemia</u>					Female	27	20.1	134.6	(88.7-195.8)
Male	9	9.8	91.4	(41.7-173.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.2	69.7	(22.5-162.7)	Female	24	22.9	104.7	(67.1-155.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	8.2	110.2	(50.3-209.2)	Male	343	371.0	92.4	(82.9-102.8)
Female	0	2.5	nc	(nc-nc)	Female	357	345.4	103.4	(92.9-114.7)
<u>Lung and Bronchus</u>									
Male	50	49.0	102.1	(75.8-134.6)					
Female	44	45.3	97.2	(70.6-130.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.0	100.8	(32.5-235.3)	Male	2	3.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	20	21.6	92.4	(56.4-142.8)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	7	6.5	107.7	(43.1-221.8)	<u>Ovary</u>				
Female	5	6.9	72.8	(23.5-169.8)	Female	1	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	15	20.2	74.2	(41.5-122.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.8	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.6	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	54	70.9	76.1	(57.2-99.3)
Female	0	0.6	nc	(nc-nc)	Female	49	76.2	64.3	(47.6-85.0)
<u>Lung and Bronchus</u>									
Male	6	9.3	64.7	(23.6-140.8)					
Female	6	11.3	52.9	(19.3-115.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	13.4	133.8	(79.3-211.5)	Male	16	9.6	166.8	(95.3-270.9)
Female	9	4.1	218.0	(99.5-413.9)	Female	9	6.8	132.4	(60.4-251.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.9	175.1	(56.4-408.7)	Male	0	2.3	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	8.3	145.2	(75.0-253.7)
Female	62	49.3	125.7	(96.4-161.2)	Female	7	5.6	124.8	(50.0-257.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	1	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.3	nc	(nc-nc)
Male	24	16.9	141.8	(90.8-211.0)	<u>Ovary</u>				
Female	14	13.8	101.4	(55.4-170.2)	Female	4	4.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.9	128.7	(41.5-300.3)	Male	4	4.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	54	57.7	93.6	(70.3-122.2)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.2	nc	(nc-nc)
Male	9	8.2	110.2	(50.3-209.1)	Female	1	1.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	13	9.5	136.1	(72.4-232.8)
Male	6	5.0	119.0	(43.4-259.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.3	nc	(nc-nc)	Female	11	11.1	99.5	(49.6-178.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.4	nc	(nc-nc)	Male	212	195.4	108.5	(94.4-124.1)
Female	2	1.2	nc	(nc-nc)	Female	182	162.6	112.0	(96.3-129.5)
<u>Lung and Bronchus</u>									
Male	23	25.8	89.1	(56.4-133.6)					
Female	12	21.5	55.9	(28.9-97.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	28.9	72.7	(45.0-111.1)	Male	10	19.2	52.0	(24.9-95.7)
Female	6	10.6	56.6	(20.7-123.3)	Female	15	16.6	90.4	(50.6-149.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.5	91.1	(29.4-212.6)	Male	7	4.9	144.3	(57.8-297.3)
Female	8	5.1	157.5	(67.8-310.3)	Female	7	3.9	180.7	(72.4-372.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	16	16.7	95.6	(54.6-155.3)
Female	121	114.0	106.1	(88.0-126.8)	Female	18	14.1	128.0	(75.8-202.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.4	112.9	(36.4-263.5)	Male	11	12.1	91.1	(45.4-163.0)
<u>Colon / Rectum</u>					Female	8	5.6	141.6	(61.0-279.0)
Male	36	35.3	101.9	(71.3-141.0)	<u>Ovary</u>				
Female	37	35.7	103.8	(73.1-143.0)	Female	16	11.2	143.4	(81.9-232.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	7.8	166.2	(88.4-284.3)	Male	11	9.4	116.9	(58.3-209.2)
Female	5	2.1	233.7	(75.3-545.5)	Female	16	10.1	158.9	(90.8-258.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	107	115.1	92.9	(76.2-112.3)
Female	1	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.8	nc	(nc-nc)
Male	19	15.9	119.4	(71.8-186.5)	Female	5	4.1	123.2	(39.7-287.5)
Female	12	9.3	129.1	(66.6-225.5)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.8	157.1	(57.4-342.0)
Male	2	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
<u>Leukemia</u>					Female	17	21.7	78.3	(45.6-125.4)
Male	9	10.6	85.2	(38.9-161.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.1	124.0	(59.4-228.0)	Female	26	26.4	98.4	(64.3-144.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	8.6	127.5	(63.6-228.2)	Male	363	397.7	91.3	(82.1-101.2)
Female	0	2.9	nc	(nc-nc)	Female	420	394.6	106.4	(96.5-117.1)
<u>Lung and Bronchus</u>									
Male	44	53.3	82.5	(60.0-110.8)					
Female	57	53.5	106.5	(80.6-137.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.6	95.0	(49.0-166.0)	Male	5	9.3	53.6	(17.3-125.2)
Female	6	4.9	123.4	(45.0-268.5)	Female	10	7.7	129.9	(62.2-239.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	8.1	74.1	(27.1-161.3)
Female	51	56.3	90.6	(67.5-119.1)	Female	3	6.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	2.7	184.5	(59.5-430.6)
Male	17	16.4	103.4	(60.2-165.5)	<u>Ovary</u>				
Female	27	16.0	169.2	(111.5-246.2)	Female	4	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.7	nc	(nc-nc)	Male	5	4.3	116.7	(37.6-272.2)
Female	1	1.0	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	64	53.6	119.5	(92.0-152.5)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.1	162.0	(52.2-378.1)
Male	5	7.9	63.5	(20.5-148.2)	Female	3	1.8	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.1	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	5	10.6	47.4	(15.3-110.5)
Male	9	5.0	178.5	(81.4-338.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.8	nc	(nc-nc)	Female	12	13.1	91.8	(47.4-160.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.3	nc	(nc-nc)	Male	184	186.4	98.7	(85.0-114.1)
Female	0	1.4	nc	(nc-nc)	Female	172	187.8	91.6	(78.4-106.4)
<u>Lung and Bronchus</u>									
Male	24	23.9	100.2	(64.2-149.2)					
Female	14	25.6	54.7	(29.9-91.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	14.0	128.4	(76.0-202.9)	Male	9	9.6	93.9	(42.9-178.3)
Female	6	5.6	106.6	(38.9-232.0)	Female	4	8.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.9	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	8.4	95.7	(41.2-188.7)
Female	66	57.8	114.2	(88.3-145.3)	Female	10	7.2	138.4	(66.3-254.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	7	6.0	116.8	(46.8-240.6)
<u>Colon / Rectum</u>					Female	5	2.8	176.0	(56.7-410.7)
Male	18	17.8	101.2	(60.0-160.0)	<u>Ovary</u>				
Female	19	19.3	98.5	(59.3-153.9)	Female	7	5.5	127.1	(50.9-261.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	3.7	214.2	(92.2-422.1)	Male	6	4.6	130.8	(47.8-284.7)
Female	1	1.1	nc	(nc-nc)	Female	6	5.4	111.2	(40.6-242.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.3	nc	(nc-nc)	Male	61	54.2	112.5	(86.1-144.6)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	3.4	nc	(nc-nc)
Male	10	7.9	126.3	(60.5-232.3)	Female	3	2.2	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.2	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	15	10.5	143.1	(80.1-236.1)
Male	11	5.5	201.2	(100.3-359.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.4	nc	(nc-nc)	Female	11	12.4	88.4	(44.1-158.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.2	165.6	(66.3-341.1)	Male	230	194.4	118.3	(103.5-134.7)
Female	3	1.5	nc	(nc-nc)	Female	215	201.6	106.7	(92.9-121.9)
<u>Lung and Bronchus</u>									
Male	29	25.5	113.6	(76.0-163.1)					
Female	34	27.7	122.9	(85.1-171.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	14	12.3	114.2	(62.4-191.7)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Ovary</u>				
Female	6	3.4	174.9	(63.8-380.6)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	19	16.1	118.0	(71.0-184.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	5	2.8	177.4	(57.2-414.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	45	52.0	86.6	(63.1-115.8)
Female	1	0.3	nc	(nc-nc)	Female	41	41.0	100.0	(71.8-135.7)
<u>Lung and Bronchus</u>									
Male	5	6.8	73.2	(23.6-170.8)					
Female	3	5.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	14.2	63.4	(28.9-120.4)	Male	10	10.8	92.3	(44.2-169.7)
Female	6	6.5	92.2	(33.7-200.8)	Female	21	10.0	210.2	(130.1-321.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	9.5	52.7	(17.0-122.9)
Female	66	72.1	91.5	(70.8-116.4)	Female	9	8.6	104.9	(47.9-199.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.9	nc	(nc-nc)	Male	4	7.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	30	18.6	161.6	(109.0-230.7)	<u>Ovary</u>				
Female	27	22.0	122.8	(80.9-178.7)	Female	8	6.8	117.3	(50.5-231.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.3	117.3	(37.8-273.8)	Male	6	4.8	124.1	(45.3-270.2)
Female	2	1.3	nc	(nc-nc)	Female	1	6.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	70	62.6	111.8	(87.1-141.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.5	nc	(nc-nc)
Male	11	9.2	119.9	(59.8-214.6)	Female	1	2.5	nc	(nc-nc)
Female	6	5.7	105.0	(38.3-228.6)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.8	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	13	13.5	96.5	(51.3-165.1)
Male	4	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.2	nc	(nc-nc)	Female	17	16.1	105.9	(61.6-169.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	5.0	198.7	(95.1-365.4)	Male	234	215.7	108.5	(95.0-123.3)
Female	0	1.8	nc	(nc-nc)	Female	229	244.2	93.8	(82.0-106.8)
<u>Lung and Bronchus</u>									
Male	35	27.3	128.4	(89.4-178.6)					
Female	19	32.6	58.4	(35.1-91.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.9	77.7	(37.2-142.9)	Male	11	8.4	131.5	(65.5-235.3)
Female	1	4.5	nc	(nc-nc)	Female	10	6.1	165.1	(79.0-303.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.3	nc	(nc-nc)
Female	37	46.4	79.7	(56.1-109.9)	Female	6	5.7	105.5	(38.5-229.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	7	5.4	130.5	(52.3-268.8)
<u>Colon / Rectum</u>					Female	5	2.3	216.7	(69.8-505.6)
Male	22	15.5	142.0	(88.9-215.0)	<u>Ovary</u>				
Female	21	14.8	141.7	(87.7-216.7)	Female	7	4.5	156.7	(62.8-322.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.5	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	5	4.2	118.4	(38.2-276.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	49	51.6	94.9	(70.2-125.5)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	8	7.1	112.4	(48.4-221.5)	Female	1	1.7	nc	(nc-nc)
Female	6	3.8	158.8	(58.0-345.8)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	10	7.6	131.4	(62.9-241.7)
Male	6	4.6	131.3	(48.0-285.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	3.3	242.1	(104.2-477.1)	Female	8	10.9	73.7	(31.7-145.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.9	nc	(nc-nc)	Male	154	175.9	87.6	(74.3-102.5)
Female	3	1.2	nc	(nc-nc)	Female	168	159.1	105.6	(90.2-122.8)
<u>Lung and Bronchus</u>									
Male	14	24.1	58.0	(31.7-97.3)					
Female	21	22.1	95.0	(58.8-145.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	34.9	68.8	(44.1-102.4)	Male	25	22.0	113.5	(73.4-167.5)
Female	16	13.9	114.8	(65.6-186.5)	Female	21	17.6	119.4	(73.9-182.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.3	110.8	(44.4-228.3)	Male	5	5.6	89.7	(28.9-209.4)
Female	11	5.5	199.6	(99.5-357.1)	Female	6	4.9	121.7	(44.4-264.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	27	19.3	139.8	(92.1-203.4)
Female	140	126.7	110.5	(93.0-130.4)	Female	16	17.2	93.1	(53.2-151.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.6	153.3	(61.4-315.9)	Male	14	12.7	110.2	(60.2-185.0)
<u>Colon / Rectum</u>					Female	5	6.6	75.9	(24.5-177.1)
Male	46	41.1	111.8	(81.9-149.1)	<u>Ovary</u>				
Female	46	46.3	99.3	(72.7-132.5)	Female	21	12.5	167.4	(103.6-256.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	8.6	128.6	(64.1-230.1)	Male	13	11.0	118.2	(62.9-202.2)
Female	2	2.9	nc	(nc-nc)	Female	14	13.4	104.6	(57.1-175.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.8	nc	(nc-nc)	Male	106	120.2	88.2	(72.2-106.7)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	8.0	100.1	(43.1-197.2)
Male	22	17.7	124.1	(77.8-188.0)	Female	11	5.5	201.5	(100.4-360.5)
Female	10	11.0	91.2	(43.6-167.7)	<u>Testis</u>				
<u>Larynx</u>					Male	10	4.8	209.4	(100.2-385.1)
Male	6	5.0	121.1	(44.2-263.6)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<u>Leukemia</u>					Female	21	20.6	102.0	(63.1-155.9)
Male	11	12.5	88.0	(43.8-157.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	10.0	70.2	(28.1-144.6)	Female	33	28.4	116.3	(80.0-163.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.3	118.6	(59.1-212.3)	Male	467	447.6	104.3	(95.1-114.2)
Female	3	3.6	nc	(nc-nc)	Female	533	462.4	115.3	(105.7-125.5)
<u>Lung and Bronchus</u>									
Male	79	62.4	126.7	(100.3-157.9)					
Female	90	68.5	131.3	(105.6-161.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.3	nc	(nc-nc)	Male	7	2.6	267.1	(107.0-550.4)
Female	2	2.3	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	15	19.0	79.0	(44.2-130.3)	Female	3	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	5	5.0	100.0	(32.2-233.3)	<u>Ovary</u>				
Female	7	7.7	91.3	(36.6-188.1)	Female	1	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.0	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	19	14.8	128.3	(77.2-200.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.0	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.6	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.1	nc	(nc-nc)	Male	68	54.4	125.1	(97.1-158.6)
Female	0	0.6	nc	(nc-nc)	Female	63	72.4	87.1	(66.9-111.4)
<u>Lung and Bronchus</u>									
Male	6	7.8	76.5	(27.9-166.5)					
Female	7	10.9	64.4	(25.8-132.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	7.5	106.7	(45.9-210.2)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	10	7.4	134.9	(64.6-248.1)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	3	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.5	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	26	24.9	104.6	(68.3-153.2)
Female	0	0.2	nc	(nc-nc)	Female	19	24.1	78.9	(47.5-123.3)
<u>Lung and Bronchus</u>									
Male	2	3.2	nc	(nc-nc)					
Female	0	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	7.7	193.8	(108.4-319.6)	Male	4	5.2	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.5	111.1	(35.8-259.2)
Female	25	35.4	70.6	(45.7-104.3)	Female	2	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	15	9.5	158.5	(88.6-261.4)	<u>Ovary</u>				
Female	6	11.4	52.8	(19.3-114.9)	Female	1	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	30	32.0	93.9	(63.3-134.0)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.3	111.1	(44.5-229.0)
Male	1	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	12	8.1	148.8	(76.8-260.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.4	nc	(nc-nc)	Male	106	108.6	97.6	(79.9-118.1)
Female	0	0.9	nc	(nc-nc)	Female	88	123.1	71.5	(57.4-88.1)
<u>Lung and Bronchus</u>									
Male	18	14.5	124.0	(73.4-196.0)					
Female	15	17.4	86.1	(48.2-142.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.7	107.8	(63.9-170.4)	Male	13	9.2	140.8	(74.9-240.7)
Female	10	6.2	161.0	(77.1-296.1)	Female	11	6.2	177.4	(88.4-317.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.9	88.9	(35.6-183.1)
Female	72	49.8	144.5	(113.0-181.9)	Female	9	7.3	123.3	(56.3-234.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	5.1	97.6	(31.4-227.7)
<u>Colon / Rectum</u>					Female	5	2.7	183.4	(59.1-428.0)
Male	15	18.5	81.0	(45.3-133.6)	<u>Ovary</u>				
Female	19	19.1	99.6	(59.9-155.5)	Female	5	5.1	98.8	(31.8-230.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.0	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	76	57.6	131.9	(103.9-165.1)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.6	nc	(nc-nc)
Male	8	7.4	107.4	(46.3-211.7)	Female	1	2.2	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.7	nc	(nc-nc)
Male	3	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.8	nc	(nc-nc)	Female	16	12.3	129.6	(74.0-210.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.0	nc	(nc-nc)	Male	207	201.2	102.9	(89.3-117.9)
Female	1	1.5	nc	(nc-nc)	Female	202	188.8	107.0	(92.8-122.8)
<u>Lung and Bronchus</u>									
Male	17	30.2	56.2	(32.7-90.0)					
Female	19	32.3	58.9	(35.4-92.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	3	7.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	11	7.7	142.9	(71.2-255.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	27	25.0	108.0	(71.2-157.2)
Female	1	0.2	nc	(nc-nc)	Female	18	22.6	79.7	(47.2-126.0)
<u>Lung and Bronchus</u>									
Male	3	3.4	nc	(nc-nc)					
Female	3	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.0	114.4	(65.3-185.8)	Male	5	9.9	50.7	(16.4-118.4)
Female	7	4.3	161.3	(64.6-332.4)	Female	5	7.2	69.2	(22.3-161.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	12	8.5	140.7	(72.6-245.9)
Female	49	50.5	97.0	(71.8-128.3)	Female	4	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	11	6.5	170.2	(84.8-304.5)
<u>Colon / Rectum</u>					Female	2	2.5	nc	(nc-nc)
Male	9	17.7	50.7	(23.2-96.3)	<u>Ovary</u>				
Female	13	14.8	87.6	(46.6-149.9)	Female	2	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.0	123.5	(39.8-288.2)	Male	3	4.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	42	60.6	69.3	(49.9-93.7)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.3	nc	(nc-nc)
Male	7	8.3	84.5	(33.8-174.0)	Female	1	1.7	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.6	nc	(nc-nc)	Male	8	3.4	233.9	(100.7-460.9)
<u>Leukemia</u>					Female	2	10.2	nc	(nc-nc)
Male	5	5.3	93.6	(30.2-218.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.5	nc	(nc-nc)	Female	12	11.6	103.7	(53.5-181.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.6	nc	(nc-nc)	Male	194	203.5	95.3	(82.4-109.7)
Female	0	1.3	nc	(nc-nc)	Female	165	170.2	96.9	(82.7-112.9)
<u>Lung and Bronchus</u>									
Male	33	26.6	124.1	(85.4-174.2)					
Female	31	22.3	138.9	(94.4-197.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	15.8	101.1	(57.8-164.3)	Male	9	9.9	90.6	(41.3-172.0)
Female	4	6.5	nc	(nc-nc)	Female	12	8.2	145.6	(75.2-254.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.8	67.9	(24.8-147.8)
Female	45	59.3	75.9	(55.4-101.6)	Female	8	8.0	100.1	(43.1-197.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	7	5.9	118.7	(47.6-244.7)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	11	19.1	57.7	(28.8-103.3)	<u>Ovary</u>				
Female	15	21.9	68.5	(38.3-113.0)	Female	1	5.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.9	nc	(nc-nc)	Male	5	5.0	99.6	(32.1-232.5)
Female	1	1.3	nc	(nc-nc)	Female	6	6.2	96.2	(35.1-209.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	40	53.8	74.4	(53.1-101.3)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.7	nc	(nc-nc)
Male	6	8.0	75.4	(27.5-164.0)	Female	0	2.6	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.6	93.5	(42.7-177.5)
Male	3	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.7	nc	(nc-nc)	Female	13	13.2	98.3	(52.3-168.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.2	nc	(nc-nc)	Male	171	202.4	84.5	(72.3-98.2)
Female	1	1.7	nc	(nc-nc)	Female	165	215.2	76.7	(65.4-89.3)
<u>Lung and Bronchus</u>									
Male	33	27.6	119.4	(82.2-167.7)					
Female	25	30.8	81.1	(52.5-119.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.7	105.2	(42.2-216.9)	Male	1	4.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	20	18.6	107.6	(65.7-166.2)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	3	7.6	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.7	105.2	(38.4-229.0)	Female	2	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	25.3	75.1	(45.2-117.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.3	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.3	nc	(nc-nc)	Female	7	4.4	158.6	(63.5-326.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	59	86.7	68.1	(51.8-87.8)
Female	1	0.5	nc	(nc-nc)	Female	52	63.7	81.6	(61.0-107.0)
<u>Lung and Bronchus</u>									
Male	6	12.1	49.6	(18.1-107.9)					
Female	3	8.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	70	68.4	102.4	(79.8-129.3)	Male	41	42.0	97.5	(70.0-132.3)
Female	31	29.4	105.5	(71.7-149.8)	Female	42	35.6	117.9	(85.0-159.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	11.7	120.0	(65.6-201.4)	Male	10	11.0	91.1	(43.6-167.6)
Female	6	11.1	53.9	(19.7-117.3)	Female	14	10.4	134.0	(73.2-224.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.0	nc	(nc-nc)	Male	47	36.8	127.8	(93.9-170.0)
Female	247	259.8	95.1	(83.6-107.7)	Female	54	35.9	150.3	(112.9-196.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	8.9	78.4	(31.4-161.5)	Male	21	24.8	84.8	(52.5-129.6)
<u>Colon / Rectum</u>					Female	11	13.5	81.5	(40.6-145.8)
Male	91	79.7	114.1	(91.9-140.1)	<u>Ovary</u>				
Female	87	98.7	88.1	(70.6-108.7)	Female	21	25.7	81.6	(50.5-124.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	17.0	59.0	(28.2-108.5)	Male	22	21.8	100.9	(63.2-152.8)
Female	4	6.1	nc	(nc-nc)	Female	33	28.4	116.1	(79.9-163.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.8	nc	(nc-nc)	Male	256	240.1	106.6	(94.0-120.5)
Female	3	4.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	22	15.4	142.7	(89.4-216.0)
Male	56	33.9	165.2	(124.8-214.6)	Female	9	11.6	77.8	(35.5-147.7)
Female	35	22.7	154.1	(107.3-214.3)	<u>Testis</u>				
<u>Larynx</u>					Male	8	7.1	112.7	(48.5-222.0)
Male	13	9.7	133.7	(71.1-228.7)	<u>Thyroid</u>				
Female	3	3.1	nc	(nc-nc)	Male	11	12.5	88.3	(44.0-157.9)
<u>Leukemia</u>					Female	44	39.8	110.5	(80.3-148.4)
Male	37	23.9	154.5	(108.8-213.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	30	20.7	144.8	(97.7-206.7)	Female	70	57.5	121.7	(94.9-153.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	20	18.3	109.2	(66.7-168.6)	Male	975	871.3	111.9	(105.0-119.2)
Female	7	7.6	91.8	(36.8-189.2)	Female	1025	956.3	107.2	(100.7-113.9)
<u>Lung and Bronchus</u>									
Male	131	122.5	106.9	(89.4-126.9)					
Female	171	143.2	119.5	(102.2-138.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	5	7.1	70.8	(22.8-165.1)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	7.2	125.4	(57.2-238.0)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	23.8	79.8	(48.0-124.6)
Female	0	0.2	nc	(nc-nc)	Female	19	23.8	80.0	(48.1-124.9)
<u>Lung and Bronchus</u>									
Male	1	3.3	nc	(nc-nc)					
Female	2	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	15.9	125.9	(76.9-194.4)	Male	15	11.7	128.4	(71.8-211.8)
Female	5	5.7	87.6	(28.2-204.5)	Female	6	9.7	62.1	(22.7-135.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.7	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	14	10.2	137.8	(75.3-231.3)
Female	80	69.8	114.6	(90.9-142.7)	Female	7	7.9	88.8	(35.6-183.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.9	nc	(nc-nc)	Male	7	7.7	90.6	(36.3-186.7)
<u>Colon / Rectum</u>					Female	1	3.3	nc	(nc-nc)
Male	26	20.3	127.9	(83.5-187.4)	<u>Ovary</u>				
Female	18	19.0	94.6	(56.1-149.6)	Female	5	6.4	77.9	(25.1-181.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.7	107.2	(34.5-250.1)	Male	6	5.3	112.6	(41.1-245.1)
Female	1	1.2	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	83	68.4	121.3	(96.6-150.4)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.8	nc	(nc-nc)
Male	9	10.0	90.0	(41.1-170.8)	Female	2	2.1	nc	(nc-nc)
Female	5	5.5	91.7	(29.5-213.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	18	13.6	132.0	(78.2-208.6)
Male	6	6.3	95.8	(35.0-208.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.6	nc	(nc-nc)	Female	17	15.7	108.1	(63.0-173.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	5.4	147.1	(63.3-289.8)	Male	262	235.0	111.5	(98.4-125.8)
Female	0	1.7	nc	(nc-nc)	Female	241	228.8	105.4	(92.5-119.5)
<u>Lung and Bronchus</u>									
Male	37	30.5	121.2	(85.4-167.1)					
Female	42	30.5	137.5	(99.1-185.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	8.5	176.7	(98.8-291.5)	Male	4	6.7	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.8	138.8	(59.8-273.5)
Female	44	39.4	111.8	(81.2-150.1)	Female	5	4.1	121.7	(39.2-283.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	1.8	335.8	(122.6-730.9)
Male	9	11.3	79.7	(36.4-151.3)	<u>Ovary</u>				
Female	8	9.4	85.4	(36.8-168.3)	Female	0	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	2.6	192.6	(62.1-449.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	35	40.0	87.4	(60.9-121.6)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	2.1	236.9	(76.3-552.7)
Male	5	5.8	86.2	(27.8-201.3)	Female	0	1.0	nc	(nc-nc)
Female	5	3.0	167.8	(54.1-391.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	6	8.3	72.0	(26.3-156.7)
Male	4	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	4	9.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.2	nc	(nc-nc)	Male	133	133.6	99.5	(83.3-117.9)
Female	1	0.9	nc	(nc-nc)	Female	132	124.1	106.4	(89.0-126.1)
<u>Lung and Bronchus</u>									
Male	15	16.6	90.2	(50.4-148.8)					
Female	19	15.7	120.8	(72.7-188.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	11.7	51.4	(18.8-111.9)
Female	0	0.1	nc	(nc-nc)	Female	9	9.7	92.6	(42.2-175.8)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	9	10.1	89.4	(40.8-169.7)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	5.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	6	5.7	105.2	(38.4-229.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	20	18.8	106.4	(65.0-164.3)
Female	0	0.3	nc	(nc-nc)	Female	21	42.1	49.9	(30.9-76.3)
<u>Lung and Bronchus</u>									
Male	3	2.6	nc	(nc-nc)					
Female	2	6.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	5	6.3	78.9	(25.4-184.0)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	7.2	96.7	(38.8-199.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	16	25.7	62.2	(35.5-101.0)
Female	0	0.1	nc	(nc-nc)	Female	19	20.6	92.3	(55.5-144.1)
<u>Lung and Bronchus</u>									
Male	0	3.3	nc	(nc-nc)					
Female	4	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	62	55.2	112.2	(86.1-143.9)	Male	38	34.4	110.4	(78.1-151.6)
Female	24	22.5	106.5	(68.2-158.4)	Female	35	28.4	123.4	(86.0-171.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	9.6	124.9	(64.5-218.2)	Male	9	8.9	100.8	(46.0-191.3)
Female	7	9.0	78.1	(31.3-160.9)	Female	4	8.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	35	30.0	116.8	(81.3-162.5)
Female	222	208.6	106.4	(92.9-121.4)	Female	28	28.1	99.7	(66.3-144.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	7.3	178.1	(94.7-304.5)	Male	28	20.4	137.2	(91.2-198.4)
<u>Colon / Rectum</u>					Female	7	10.8	64.9	(26.0-133.8)
Male	82	64.8	126.6	(100.7-157.2)	<u>Ovary</u>				
Female	88	73.3	120.0	(96.2-147.8)	Female	15	20.5	73.3	(41.0-121.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	13.9	150.6	(93.2-230.2)	Male	19	17.6	107.7	(64.8-168.2)
Female	2	4.7	nc	(nc-nc)	Female	24	21.4	111.9	(71.7-166.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.9	127.2	(41.0-296.9)	Male	206	199.8	103.1	(89.5-118.2)
Female	2	3.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	12.5	71.9	(32.8-136.4)
Male	34	28.0	121.5	(84.2-169.9)	Female	7	8.5	82.4	(33.0-169.8)
Female	14	18.2	77.1	(42.1-129.3)	<u>Testis</u>				
<u>Larynx</u>					Male	9	6.0	149.6	(68.3-284.1)
Male	6	8.0	74.7	(27.3-162.5)	<u>Thyroid</u>				
Female	2	2.6	nc	(nc-nc)	Male	11	10.4	105.7	(52.7-189.2)
<u>Leukemia</u>					Female	28	33.1	84.5	(56.1-122.1)
Male	20	19.4	103.2	(63.0-159.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	15.9	75.3	(38.9-131.5)	Female	48	47.9	100.2	(73.9-132.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	15.1	119.3	(70.7-188.5)	Male	798	714.7	111.7	(104.0-119.7)
Female	7	5.9	117.8	(47.2-242.7)	Female	798	754.2	105.8	(98.6-113.4)
<u>Lung and Bronchus</u>									
Male	120	100.2	119.7	(99.3-143.2)					
Female	138	114.0	121.0	(101.7-143.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.5	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	15.7	101.7	(58.1-165.1)
Female	0	0.1	nc	(nc-nc)	Female	9	12.6	71.3	(32.5-135.3)
<u>Lung and Bronchus</u>									
Male	6	2.2	269.9	(98.6-587.5)					
Female	2	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.5	119.9	(54.7-227.6)	Male	3	5.2	nc	(nc-nc)
Female	5	4.0	124.6	(40.1-290.7)	Female	5	5.2	96.1	(31.0-224.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.5	156.3	(62.6-322.0)
Female	27	36.9	73.1	(48.2-106.4)	Female	4	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	6	3.3	184.2	(67.2-400.9)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	5	9.4	53.2	(17.1-124.1)	<u>Ovary</u>				
Female	8	13.2	60.7	(26.1-119.6)	Female	2	3.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	37	30.3	122.3	(86.1-168.5)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.8	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	5	1.8	276.4	(89.1-645.0)
<u>Leukemia</u>					Female	3	6.2	nc	(nc-nc)
Male	6	2.8	212.3	(77.5-462.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.9	nc	(nc-nc)	Female	9	8.3	108.1	(49.3-205.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.3	nc	(nc-nc)	Male	124	105.7	117.3	(97.6-139.9)
Female	0	1.1	nc	(nc-nc)	Female	97	135.0	71.9	(58.3-87.7)
<u>Lung and Bronchus</u>									
Male	20	14.2	141.2	(86.2-218.0)					
Female	17	20.3	83.7	(48.7-134.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	64	55.8	114.7	(88.3-146.4)	Male	65	39.5	164.8	(127.2-210.0)
Female	21	21.8	96.1	(59.5-147.0)	Female	59	32.0	184.7	(140.6-238.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	11.7	68.6	(29.5-135.2)	Male	14	9.6	146.0	(79.8-245.0)
Female	9	9.9	91.2	(41.6-173.2)	Female	5	7.9	62.9	(20.3-146.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	29	33.8	85.8	(57.4-123.2)
Female	272	233.6	116.4	(103.0-131.1)	Female	36	28.5	126.3	(88.5-174.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	9.0	77.8	(31.2-160.3)	Male	27	25.3	106.9	(70.4-155.5)
<u>Colon / Rectum</u>					Female	11	11.5	95.3	(47.5-170.6)
Male	80	70.0	114.3	(90.6-142.2)	<u>Ovary</u>				
Female	81	72.2	112.1	(89.1-139.4)	Female	23	22.4	102.8	(65.1-154.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	15.9	125.4	(76.6-193.7)	Male	16	18.5	86.4	(49.4-140.3)
Female	3	4.4	nc	(nc-nc)	Female	20	20.6	97.1	(59.3-149.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	5.4	93.1	(30.0-217.3)	Male	283	239.0	118.4	(105.0-133.1)
Female	10	4.1	246.7	(118.1-453.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	19	13.4	142.1	(85.5-221.9)
Male	37	33.2	111.5	(78.5-153.7)	Female	7	8.3	84.8	(34.0-174.7)
Female	26	19.1	136.5	(89.1-200.0)	<u>Testis</u>				
<u>Larynx</u>					Male	8	9.1	88.3	(38.0-174.0)
Male	15	9.4	159.4	(89.1-262.9)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	12	13.8	87.0	(44.9-151.9)
<u>Leukemia</u>					Female	47	41.7	112.8	(82.9-150.0)
Male	23	21.0	109.3	(69.3-164.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	28	16.3	171.7	(114.0-248.1)	Female	52	54.3	95.7	(71.5-125.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	17.8	101.0	(59.8-159.6)	Male	906	807.7	112.2	(105.0-119.7)
Female	6	6.0	99.8	(36.4-217.2)	Female	917	800.2	114.6	(107.3-122.3)
<u>Lung and Bronchus</u>									
Male	109	106.3	102.6	(84.2-123.7)					
Female	118	111.5	105.8	(87.6-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	5	1.9	260.4	(83.9-607.7)
Female	0	1.0	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	9	12.0	75.3	(34.3-142.9)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	3.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.8	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	15	12.4	120.6	(67.4-198.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	44	40.4	108.9	(79.1-146.3)
Female	1	0.3	nc	(nc-nc)	Female	30	39.1	76.8	(51.8-109.6)
<u>Lung and Bronchus</u>									
Male	3	5.4	nc	(nc-nc)					
Female	8	5.5	145.0	(62.4-285.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.8	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	14	14.8	94.4	(51.6-158.4)	Female	3	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	3.7	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	17	18.0	94.3	(54.9-151.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	41	57.4	71.4	(51.3-96.9)
Female	0	0.3	nc	(nc-nc)	Female	40	47.0	85.1	(60.8-115.9)
<u>Lung and Bronchus</u>									
Male	4	7.5	nc	(nc-nc)					
Female	1	6.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	4.9	161.9	(69.7-319.0)	Male	7	3.7	188.9	(75.7-389.3)
Female	1	2.4	nc	(nc-nc)	Female	5	2.7	185.7	(59.8-433.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.1	225.3	(90.2-464.1)
Female	24	21.2	113.1	(72.4-168.3)	Female	1	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	7	2.6	269.2	(107.8-554.7)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	11	6.6	167.4	(83.5-299.6)	<u>Ovary</u>				
Female	4	7.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	17	23.3	72.8	(42.4-116.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	0	3.3	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.5	nc	(nc-nc)	Female	6	5.3	112.3	(41.0-244.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	1.8	326.7	(119.3-711.1)	Male	101	75.7	133.4	(108.6-162.1)
Female	0	0.6	nc	(nc-nc)	Female	64	76.5	83.7	(64.5-106.9)
<u>Lung and Bronchus</u>									
Male	13	9.7	133.6	(71.1-228.5)					
Female	14	11.7	120.0	(65.5-201.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	92	97.4	94.4	(76.1-115.8)	Male	66	64.8	101.9	(78.8-129.6)
Female	46	40.8	112.7	(82.5-150.4)	Female	59	56.2	105.0	(79.9-135.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.7	101.6	(61.1-158.6)	Male	16	16.1	99.4	(56.8-161.4)
Female	12	17.3	69.4	(35.8-121.1)	Female	10	14.6	68.5	(32.8-125.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.8	nc	(nc-nc)	Male	47	55.9	84.0	(61.7-111.7)
Female	364	394.9	92.2	(83.0-102.2)	Female	59	51.8	114.0	(86.8-147.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	15.3	111.0	(64.6-177.7)	Male	54	38.7	139.4	(104.7-181.9)
<u>Colon / Rectum</u>					Female	24	20.2	118.9	(76.1-176.9)
Male	137	116.5	117.6	(98.7-139.0)	<u>Ovary</u>				
Female	159	135.4	117.5	(99.9-137.2)	Female	44	38.7	113.8	(82.7-152.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	29	25.5	113.5	(76.0-163.1)	Male	32	31.4	101.9	(69.7-143.9)
Female	11	8.4	131.0	(65.3-234.4)	Female	43	38.9	110.5	(80.0-148.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	9.1	110.5	(52.9-203.2)	Male	325	368.8	88.1	(78.8-98.2)
Female	8	7.4	108.1	(46.5-212.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	31	22.5	137.8	(93.6-195.6)
Male	56	52.5	106.6	(80.5-138.5)	Female	11	15.7	70.0	(34.9-125.2)
Female	34	33.7	100.9	(69.9-141.0)	<u>Testis</u>				
<u>Larynx</u>					Male	10	15.9	63.0	(30.2-115.9)
Male	17	14.8	114.8	(66.8-183.8)	<u>Thyroid</u>				
Female	8	4.7	169.4	(72.9-333.7)	Male	14	21.6	64.8	(35.4-108.7)
<u>Leukemia</u>					Female	78	70.6	110.5	(87.3-137.9)
Male	27	35.1	76.9	(50.7-111.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	32	29.8	107.4	(73.4-151.6)	Female	99	89.3	110.8	(90.1-135.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	51	28.0	181.9	(135.4-239.2)	Male	1323	1314.2	100.7	(95.3-106.2)
Female	13	10.9	119.2	(63.4-203.9)	Female	1498	1414.8	105.9	(100.6-111.4)
<u>Lung and Bronchus</u>									
Male	185	179.1	103.3	(88.9-119.3)					
Female	245	204.7	119.7	(105.2-135.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	31.2	83.2	(54.4-122.0)	Male	20	21.1	94.7	(57.8-146.2)
Female	10	11.2	89.5	(42.9-164.7)	Female	19	17.2	110.4	(66.4-172.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.2	144.8	(66.1-275.0)	Male	5	5.2	95.3	(30.7-222.3)
Female	5	5.2	96.3	(31.0-224.8)	Female	2	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	22	18.3	119.9	(75.1-181.5)
Female	123	120.4	102.1	(84.9-121.9)	Female	19	14.7	129.3	(77.8-202.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.0	120.7	(44.1-262.8)	Male	8	12.9	62.0	(26.7-122.1)
<u>Colon / Rectum</u>					Female	2	6.0	nc	(nc-nc)
Male	47	38.7	121.5	(89.3-161.6)	<u>Ovary</u>				
Female	47	37.6	125.2	(92.0-166.4)	Female	16	11.5	138.8	(79.3-225.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.2	109.7	(50.1-208.3)	Male	16	10.2	157.5	(89.9-255.7)
Female	2	2.3	nc	(nc-nc)	Female	15	10.6	141.3	(79.0-233.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	109	117.2	93.0	(76.3-112.1)
Female	0	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	7.3	nc	(nc-nc)
Male	21	17.2	122.1	(75.6-186.7)	Female	12	4.3	277.0	(142.9-483.8)
Female	10	9.7	103.0	(49.3-189.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.9	nc	(nc-nc)
Male	6	4.8	126.0	(46.0-274.2)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	7	7.2	97.6	(39.1-201.0)
<u>Leukemia</u>					Female	25	23.2	107.8	(69.8-159.2)
Male	12	11.7	102.5	(52.9-179.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.6	104.4	(47.6-198.2)	Female	35	27.4	127.8	(89.0-177.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	9.2	152.1	(83.1-255.2)	Male	452	425.0	106.4	(96.8-116.6)
Female	5	3.1	162.7	(52.4-379.7)	Female	469	414.0	113.3	(103.3-124.0)
<u>Lung and Bronchus</u>									
Male	75	56.9	131.7	(103.6-165.1)					
Female	69	55.8	123.6	(96.2-156.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	14.5	82.6	(42.6-144.2)	Male	12	9.7	123.5	(63.8-215.8)
Female	3	4.5	nc	(nc-nc)	Female	7	7.2	97.4	(39.0-200.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	5	2.2	224.5	(72.4-523.9)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	8.3	71.9	(26.3-156.6)
Female	50	51.5	97.2	(72.1-128.1)	Female	6	6.0	99.3	(36.2-216.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	242.1	(78.0-565.0)	Male	6	6.0	99.3	(36.3-216.2)
<u>Colon / Rectum</u>					Female	1	2.5	nc	(nc-nc)
Male	16	17.7	90.3	(51.6-146.7)	<u>Ovary</u>				
Female	12	14.4	83.3	(43.0-145.6)	Female	6	4.9	123.2	(45.0-268.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.9	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	60	57.2	104.8	(80.0-135.0)
Female	4	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.4	147.5	(47.5-344.2)
Male	11	8.1	136.0	(67.8-243.4)	Female	1	1.6	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.0	255.9	(82.5-597.2)
Male	1	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	9.8	112.2	(55.9-200.8)
Male	6	5.4	112.1	(40.9-244.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.5	171.8	(62.7-374.0)	Female	10	12.2	82.2	(39.3-151.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	198	199.5	99.3	(85.9-114.1)
Female	1	1.3	nc	(nc-nc)	Female	181	172.8	104.7	(90.0-121.1)
<u>Lung and Bronchus</u>									
Male	24	27.0	88.8	(56.9-132.1)					
Female	29	24.1	120.5	(80.7-173.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	25.9	119.5	(81.2-169.7)	Male	27	17.0	158.6	(104.5-230.7)
Female	12	9.7	123.7	(63.8-216.1)	Female	15	13.6	110.7	(61.9-182.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.0	141.0	(56.5-290.5)	Male	1	4.3	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.9	107.5	(61.4-174.6)
Female	132	99.9	132.2	(110.6-156.7)	Female	14	12.4	113.0	(61.7-189.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.7	nc	(nc-nc)	Male	10	10.5	95.1	(45.5-175.0)
<u>Colon / Rectum</u>					Female	4	4.9	nc	(nc-nc)
Male	30	31.2	96.1	(64.8-137.2)	<u>Ovary</u>				
Female	54	32.8	164.6	(123.7-214.8)	Female	6	9.5	63.0	(23.0-137.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.9	87.1	(31.8-189.7)	Male	10	8.4	119.6	(57.2-219.9)
Female	4	2.0	nc	(nc-nc)	Female	10	9.3	107.6	(51.5-197.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.1	nc	(nc-nc)	Male	103	99.1	103.9	(84.8-126.0)
Female	5	1.7	298.2	(96.1-695.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	6.0	133.3	(57.4-262.7)
Male	11	14.3	77.1	(38.4-138.0)	Female	6	3.8	157.0	(57.3-341.7)
Female	3	8.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.1	nc	(nc-nc)
Male	4	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	9	5.5	162.7	(74.2-308.8)
<u>Leukemia</u>					Female	29	17.1	169.4	(113.4-243.2)
Male	11	9.3	118.2	(58.9-211.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	7.3	150.7	(75.1-269.6)	Female	29	22.1	131.2	(87.8-188.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.7	91.1	(36.5-187.7)	Male	375	350.3	107.1	(96.5-118.5)
Female	3	2.6	nc	(nc-nc)	Female	421	345.4	121.9	(110.5-134.1)
<u>Lung and Bronchus</u>									
Male	54	48.4	111.7	(83.9-145.7)					
Female	43	48.0	89.7	(64.9-120.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.1	91.2	(45.5-163.2)	Male	10	8.6	116.4	(55.7-214.1)
Female	5	4.2	119.9	(38.6-279.8)	Female	5	6.3	79.2	(25.5-184.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.4	81.2	(29.7-176.8)
Female	53	46.6	113.8	(85.2-148.8)	Female	7	5.5	126.3	(50.6-260.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	5.7	104.4	(38.1-227.3)
<u>Colon / Rectum</u>					Female	1	2.2	nc	(nc-nc)
Male	12	15.4	77.8	(40.1-135.9)	<u>Ovary</u>				
Female	12	14.1	84.9	(43.8-148.3)	Female	3	4.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.5	nc	(nc-nc)	Male	6	4.1	147.9	(54.0-322.0)
Female	0	0.9	nc	(nc-nc)	Female	5	4.0	126.0	(40.6-294.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	56	52.7	106.3	(80.3-138.0)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.9	nc	(nc-nc)
Male	8	7.4	108.2	(46.6-213.2)	Female	2	1.6	nc	(nc-nc)
Female	5	3.7	133.5	(43.0-311.5)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	8.3	60.3	(19.4-140.8)
Male	3	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.1	nc	(nc-nc)	Female	13	10.5	123.7	(65.8-211.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.1	nc	(nc-nc)	Male	160	176.8	90.5	(77.0-105.7)
Female	3	1.2	nc	(nc-nc)	Female	153	156.8	97.6	(82.7-114.3)
<u>Lung and Bronchus</u>									
Male	23	23.1	99.4	(63.0-149.2)					
Female	20	21.6	92.7	(56.6-143.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	61.1	81.9	(60.8-108.0)	Male	23	38.4	59.9	(37.9-89.9)
Female	28	21.4	130.7	(86.9-189.0)	Female	29	29.4	98.6	(66.0-141.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.0	81.7	(37.3-155.1)	Male	10	9.8	101.8	(48.7-187.3)
Female	10	9.3	107.5	(51.5-197.7)	Female	10	7.6	131.8	(63.1-242.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	33	33.6	98.2	(67.6-138.0)
Female	216	202.0	106.9	(93.1-122.2)	Female	32	27.0	118.4	(81.0-167.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	8.1	123.5	(59.1-227.1)	Male	24	21.9	109.5	(70.1-162.9)
<u>Colon / Rectum</u>					Female	11	10.5	105.1	(52.4-188.1)
Male	76	71.5	106.3	(83.8-133.1)	<u>Ovary</u>				
Female	55	70.5	78.0	(58.8-101.6)	Female	19	20.0	94.8	(57.1-148.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	15.1	73.1	(36.4-130.7)	Male	18	19.2	93.5	(55.4-147.8)
Female	4	4.4	nc	(nc-nc)	Female	17	20.4	83.3	(48.5-133.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	4.9	182.5	(83.3-346.4)	Male	133	213.8	62.2	(52.1-73.7)
Female	4	3.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	13.9	108.2	(60.5-178.5)
Male	41	30.5	134.3	(96.3-182.2)	Female	6	8.2	72.8	(26.6-158.4)
Female	38	17.6	215.6	(152.5-295.9)	<u>Testis</u>				
<u>Larynx</u>					Male	9	8.4	107.0	(48.8-203.1)
Male	15	8.7	172.7	(96.6-284.8)	<u>Thyroid</u>				
Female	3	2.5	nc	(nc-nc)	Male	13	11.9	108.8	(57.9-186.1)
<u>Leukemia</u>					Female	33	37.0	89.1	(61.3-125.1)
Male	21	21.9	96.1	(59.4-146.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	16.0	93.7	(52.4-154.5)	Female	44	45.9	95.8	(69.6-128.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	28	16.1	173.9	(115.5-251.3)	Male	734	784.8	93.5	(86.9-100.5)
Female	6	5.7	105.6	(38.5-229.8)	Female	805	735.7	109.4	(102.0-117.2)
<u>Lung and Bronchus</u>									
Male	137	109.4	125.2	(105.1-148.1)					
Female	149	107.6	138.5	(117.2-162.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	8	9.9	81.1	(34.9-159.8)	Female	1	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	5	3.8	131.9	(42.5-307.8)	<u>Ovary</u>				
Female	5	3.2	158.7	(51.1-370.3)	Female	0	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	21	13.5	155.3	(96.1-237.4)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	41	43.8	93.6	(67.1-126.9)
Female	0	0.3	nc	(nc-nc)	Female	22	34.0	64.7	(40.5-97.9)
<u>Lung and Bronchus</u>									
Male	2	6.2	nc	(nc-nc)					
Female	1	5.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.5	90.4	(29.1-210.9)	Male	3	3.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	23	20.2	113.6	(72.0-170.5)	Female	1	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	5.6	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	26	25.2	103.3	(67.5-151.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.7	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.3	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	63	81.9	76.9	(59.1-98.4)
Female	0	0.5	nc	(nc-nc)	Female	56	67.1	83.4	(63.0-108.3)
<u>Lung and Bronchus</u>									
Male	7	10.7	65.2	(26.1-134.2)					
Female	5	9.2	54.6	(17.6-127.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	17.8	123.7	(77.5-187.3)	Male	13	11.9	109.4	(58.2-187.1)
Female	10	6.3	158.9	(76.1-292.2)	Female	12	9.8	122.1	(63.0-213.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.5	nc	(nc-nc)	Male	11	10.4	106.1	(52.9-189.9)
Female	69	70.4	98.0	(76.2-124.0)	Female	7	8.4	83.4	(33.4-171.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.8	nc	(nc-nc)	Male	7	7.1	98.7	(39.6-203.4)
<u>Colon / Rectum</u>					Female	8	3.4	233.5	(100.6-460.2)
Male	23	21.5	107.1	(67.8-160.6)	<u>Ovary</u>				
Female	28	20.7	135.3	(89.9-195.6)	Female	8	6.7	120.3	(51.8-237.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	4.6	236.8	(118.1-423.8)	Male	6	5.8	104.1	(38.0-226.6)
Female	1	1.3	nc	(nc-nc)	Female	13	5.9	220.2	(117.1-376.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	70	66.6	105.1	(81.9-132.8)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.1	nc	(nc-nc)
Male	23	9.6	239.9	(152.0-360.0)	Female	1	2.3	nc	(nc-nc)
Female	5	5.7	87.9	(28.3-205.2)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.1	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	16	13.3	120.7	(69.0-196.0)
Male	12	6.7	179.3	(92.6-313.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.7	105.4	(34.0-246.0)	Female	17	16.2	104.7	(61.0-167.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	5.2	134.4	(53.9-277.0)	Male	293	241.0	121.6	(108.1-136.3)
Female	2	1.8	nc	(nc-nc)	Female	287	238.1	120.5	(107.0-135.3)
<u>Lung and Bronchus</u>									
Male	41	32.8	124.9	(89.6-169.4)					
Female	56	32.9	170.3	(128.7-221.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	12.5	152.6	(91.8-238.3)	Male	8	7.5	107.1	(46.1-211.0)
Female	7	5.2	133.9	(53.6-275.8)	Female	7	6.2	112.7	(45.1-232.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	10	6.6	151.8	(72.7-279.1)
Female	36	47.9	75.1	(52.6-104.0)	Female	5	6.4	77.8	(25.1-181.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.4	nc	(nc-nc)
Male	20	14.6	137.1	(83.7-211.8)	<u>Ovary</u>				
Female	18	17.6	102.2	(60.5-161.5)	Female	4	4.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.2	158.5	(51.1-369.8)	Male	4	4.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	5	5.1	98.8	(31.9-230.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	40	45.3	88.3	(63.0-120.2)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.8	nc	(nc-nc)
Male	4	6.1	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Female	1	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.5	107.2	(42.9-220.8)
Male	8	4.2	188.5	(81.2-371.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.6	nc	(nc-nc)	Female	11	11.1	98.7	(49.2-176.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	165	159.1	103.7	(88.5-120.8)
Female	1	1.4	nc	(nc-nc)	Female	146	172.7	84.5	(71.4-99.4)
<u>Lung and Bronchus</u>									
Male	20	22.3	89.5	(54.6-138.2)					
Female	16	26.2	61.2	(34.9-99.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	11.7	85.3	(40.8-156.8)
Female	0	0.1	nc	(nc-nc)	Female	9	8.4	107.0	(48.8-203.2)
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.1	138.3	(55.4-284.9)	Male	1	3.8	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.3	180.7	(66.0-393.2)
Female	30	25.4	118.3	(79.8-168.9)	Female	5	3.1	162.6	(52.4-379.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	4	6.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	8.0	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	1.5	408.4	(149.1-888.9)	Male	1	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	26	21.2	122.8	(80.2-179.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.8	nc	(nc-nc)	Female	6	5.6	106.7	(39.0-232.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	78	75.2	103.7	(82.0-129.4)
Female	0	0.6	nc	(nc-nc)	Female	78	86.8	89.9	(71.0-112.2)
<u>Lung and Bronchus</u>									
Male	7	9.7	72.5	(29.0-149.3)					
Female	12	12.4	96.7	(49.9-168.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	5.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	8.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	19	27.1	70.0	(42.2-109.4)
Female	0	0.1	nc	(nc-nc)	Female	10	19.6	51.0	(24.4-93.9)
<u>Lung and Bronchus</u>									
Male	3	3.6	nc	(nc-nc)					
Female	2	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;